Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for anHLA-DRB1-METGene Fusion-Reference-Cited by-同舟云学术

Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for anHLA-DRB1-METGene Fusion

Published:2017-11 Issue:1 Volume: Page:1-6
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Davies Kurtis D.¹,Ng Terry L.¹,Estrada-Bernal Adriana¹,Le Anh T.¹,Ennever Peter R.¹,Camidge D. Ross¹,Doebele Robert C.¹,Aisner Dara L.¹

Affiliation:

1. Kurtis D. Davies, Terry L. Ng, Adriana Estrada-Bernal, Anh T. Le, D. Ross Camidge, Robert C. Doebele, and Dara L. Aisner, University of Colorado, Anschutz Medical Campus, Aurora, CO; and Peter R. Ennever, Cone Health Cancer Center, Greensboro, NC.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.17.00117

Reference22 articles.

1. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

2. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

3. Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

4. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

5. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;Nature Communications;2024-06-14

2. Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring TFG-MET fusion;International Cancer Conference Journal;2024-03-09

3. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

4. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02

5. MET fusions are targetable genomic variants in the treatment of advanced malignancies;Cell Communication and Signaling;2024-01-09